S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:CBIO

Catalyst Biosciences (CBIO) Stock Forecast, Price & News

$0.49
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.49
$0.52
50-Day Range
$0.33
$0.65
52-Week Range
$0.19
$0.74
Volume
105,048 shs
Average Volume
363,560 shs
Market Capitalization
$18.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Catalyst Biosciences MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.16) to ($0.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.27 out of 5 stars

Medical Sector

934th out of 965 stocks

Pharmaceutical Preparations Industry

445th out of 456 stocks


CBIO stock logo

About Catalyst Biosciences (NASDAQ:CBIO) Stock

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

CBIO Price History

CBIO Stock News Headlines

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
CBIO - Catalyst Biosciences, Inc.
5 Cheap Healthcare Stocks to Buy in 2023
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
12 Cheap Healthcare Stocks to Buy in 2023
Catalyst Biosciences Provides Corporate Update
Catalyst/Millburn Hedge Strategy I
5 Stocks with the Lowest PE Ratio
CBIO Catalyst Biosciences, Inc.
See More Headlines
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CBIO Company Calendar

Last Earnings
8/17/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CBIO
CUSIP
87611R30
Employees
7
Year Founded
2003

Profitability

Net Income
$-8,240,000.00
Pretax Margin
-994.21%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
36,456,000
Market Cap
$18.65 million
Optionable
Optionable
Beta
1.02

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Nassim Usman Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $1.75M
  • Ms. Seline E. Miller CPA (Age 54)
    Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
    Comp: $707.55k
  • Ms. Ana Kapor
    Sr. Director of Investor Relations & Corp. Communications













CBIO Stock - Frequently Asked Questions

How have CBIO shares performed in 2023?

Catalyst Biosciences' stock was trading at $0.5275 at the start of the year. Since then, CBIO shares have decreased by 6.9% and is now trading at $0.4912.
View the best growth stocks for 2023 here
.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 165,400 shares, an increase of 61.8% from the August 15th total of 102,200 shares. Based on an average trading volume of 709,900 shares, the days-to-cover ratio is presently 0.2 days.
View Catalyst Biosciences' Short Interest
.

When is Catalyst Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CBIO earnings forecast
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07).

How often does Catalyst Biosciences pay dividends? What is the dividend yield for Catalyst Biosciences?

Catalyst Biosciences announced a dividend on Wednesday, January 4th. Investors of record on Monday, January 16th will be given a dividend of $0.24 per share on Thursday, January 12th. This represents a yield of 285.47%. The ex-dividend date is Friday, January 13th.
Read our dividend analysis for CBIO
.

When did Catalyst Biosciences' stock split?

Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Imunon (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

Who are Catalyst Biosciences' major shareholders?

Catalyst Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.05%), Acadian Asset Management LLC (0.38%) and Simplex Trading LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Catalyst Biosciences?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $0.49.

How much money does Catalyst Biosciences make?

Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $18.65 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-8,240,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107.

This page (NASDAQ:CBIO) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -